Endoscopic minimally invasive treatment of internal hemorrhoids may cause postoperative pain. The aim of the study is to investigate the analgesic effect of lidocaine plus lauromacrogol on postoperative pain caused by endoscopic rubber band ligation (ERBL) combined with injection sclerotherapy (IS) for internal hemorrhoids treatment. Clinical data of grade Ⅲ internal hemorrhoids patients who underwent ERBL combined with IS in department of Digestive Medicine, Shenzhen Hospital of Southern Medical University, were retrospectively analyzed. According to difference in the composition of sclerosing solution, the patients were divided into control group (lauromacrogol group, 46 patients) and study group (lidocaine plus lauromacrogol group, 20 patients). Postoperative pain (quantized by Visual Analogue Scale, VAS), pain relief time and postoperative adverse reactions were compared. The therapeutic effect was followed up 1 month after operation. VAS of postoperative pain was 0.80 ± 0.42 points and pain relief time was 0.90 ± 0.56 days in the study group, while VAS of postoperative pain was 4.11 ± 1.37 points and pain relief time was 2.57 ± 0.83 days in the control group, there was statistical difference between them (P < 0.05). There was no significant difference in the incidence of postoperative adverse reactions and follow-up therapeutic effect between the control group and the study group. Lidocaine plus lauromacrogol is useful for pain alleviation on ERBL combined with IS for internal hemorrhoids treatment because of its convenient procedure, low adverse reaction incidence and good therapeutic effect, which is worthy of promotion.

中文翻译：

---

利多卡因对内镜橡皮筋结扎联合注射硬化剂治疗内痔术后镇痛效果的回顾性研究（附视频）

内痔微创治疗可能会引起术后疼痛。本研究旨在探讨利多卡因联合聚桂醇对内镜橡皮筋结扎术（ERBL）联合注射硬化剂治疗（IS）治疗内痔术后疼痛的镇痛效果。回顾性分析南方医科大学深圳医院消化内科接受ERBL联合IS治疗的Ⅲ级内痔患者的临床资料。根据硬化液成分的差异，将患​​者分为对照组（聚桂醇组，46例）和研究组（利多卡因加聚桂醇组，20例）。比较术后疼痛（视觉模拟量表，VAS量化）、疼痛缓解时间和术后不良反应。术后1个月随访疗效。研究组术后疼痛VAS为0.80±0.42分,疼痛缓解时间为0.90±0.56天,对照组术后疼痛VAS为4.11±1.37分,疼痛缓解时间为2.57±0.83天,有统计学意义之间的差异（P<0.05）。对照组与研究组术后不良反应发生率及随访治疗效果无显着差异。利多卡因联合聚桂醇用于ERBL联合IS治疗内痔的止痛方法，操作简便，不良反应发生率低，治疗效果好，值得推广。